Medical representatives barred from govt hospitals to stop pharma influence

Medical representatives will no longer be permitted to meet doctors directly within central government hospitals, following a directive from the Centre aimed at putting an end to the nexus between pharmaceutical companies and medical professionals, reported The Economic Times. The move seeks to curtail any influence exerted through gifts or free samples.

According to the report, the Directorate General of Health Services (DGHS) has instructed all government-run hospitals to bar the entry of medical representatives. Instead, if pharmaceutical companies wish to share information about new treatments or medical advancements, they must do so through email or other digital media.

DGHS’s directive on disruptions and influence

The order, dated May 28, directs heads of government medical institutions to ensure full compliance with the new policy. The directive also aims to put an end to disruptions to hospital operations caused by unregulated interactions between pharma representatives and doctors.

Last year, the Department of Pharmaceuticals implemented the Uniform Code for Pharmaceuticals Marketing Practices (UCPMP), which bars pharmaceutical companies from offering gifts or travel perks to healthcare professionals or their relatives. The code also prohibits the provision of cash or monetary grants to doctors or their family members under any circumstances.

The UCPMP also bans the distribution of free drug samples to individuals who are not authorised to prescribe them.

Doctors must prescribe only generic drugs: SC

In May, the Supreme Court declared that doctors across the country should be mandated to prescribe only generic medicines rather than branded alternatives. Generic drugs are designed to match their branded counterparts in terms of dosage, safety, efficacy, administration method, and therapeutic use.

The observation came during the hearing of a Public Interest Litigation (PIL) seeking tighter control over the marketing and promotional strategies employed by pharmaceutical companies.

NMC directive on generic medicines withdrawn

In 2023, the National Medical Commission (NMC) introduced new regulations under the ‘Professional Conduct of Registered Medical Practitioners’, requiring doctors to prescribe only generic medicines. The guidelines warned that failure to comply could lead to penalties, including suspension of medical licences.

However, the Indian Medical Association (IMA) strongly opposed the government’s directive. The body questioned the rationale behind continuing to licence branded medications if the government aims to prioritise generics.

Following widespread backlash from the medical community, the NMC was forced to put the implementation of these guidelines on hold.

Related Posts

Gene Therapy for Cholesterol: Initial Test Results Cheer

Eli Lilly working on single-dose drug to be administered via IV for long-term gain Mumbai: For millions of heart patients struggling with elevated levels of cholesterol, there is a ray…

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Regeneron Pharmaceuticals, Inc. has announced plans to establish the Regeneron Global Capability Centre (GCC) in Hyderabad, a strategic investment that deepens its global operations and scales business functions to advance…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Gene Therapy for Cholesterol: Initial Test Results Cheer

Gene Therapy for Cholesterol: Initial Test Results Cheer

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

STF busts fake meds racket spread across 6 states

STF busts fake meds racket spread across 6 states